Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 12/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284899 | 0.85 | MAPT (0.76) | MAPTLCK | |
| SCHEMBL23183609 | 0.85 | DYRK1A (0.67) | MAPTLCKDYRK1ARETFLT1 | |
| SCHEMBL3283781 | 0.84 | MAPT (0.55) | MAPTLCKDYRK1A | |
| SCHEMBL1284898 | 0.84 | MAPT (0.55) | MAPTLCKDYRK1A | |
| SCHEMBL23974266 | 0.84 | LCK (0.56) | MAPTLCKDYRK1A | |
| SCHEMBL29454481 | 0.84 | LCK (0.56) | MAPTLCKDYRK1A | |
| SCHEMBL3053547 | 0.82 | DYRK1A (0.70) | MAPTLCKDYRK1A | |
| SCHEMBL21839507 | 0.82 | MAPT (0.54) | MAPTLCKDYRK1A | |
| SCHEMBL16743933 | 0.82 | MEN1 (0.62) | MAPTLCKDYRK1A | |
| SCHEMBL31733133 | 0.81 | MAPT (0.53) | MAPTLCKDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-8293743-B2 | Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells | CHOONGWAE PHARMA CORPORATION (KR) | 2012-10-23 | — | — | US | disclosed |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1957516-A2 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | Choongwae Pharma Corporation (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
| WO-2007056513-A1 | α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | INSTITUTE FOR CHEMICAL GENOMICS (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056593-A2 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | MAPT 2446/4885LCK 4331/4885DYRK1A 4772/4885 |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | MAPT 4304/4885LCK 3163/4885DYRK1A 2518/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | MAPT 2031/4885LCK 4738/4885DYRK1A 4476/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | MAPT 4249/4885LCK 3139/4885DYRK1A 2144/4885 |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | MCL1, HNF4A, THPO | MAPT 2031/4885LCK 4721/4885DYRK1A 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.